Illustrative image of Brickell Key and the Miami skyline; it does not depict MoonLake’s office.
MoonLake Immunotherapeutics plans to establish its U.S. headquarters on Brickell Key, taking 13,500 square feet at Brickell Key Centre II and hiring up to 75 employees for the location, according to the South Florida Business Journal’s Nov. 6 report.
The planned office will support MoonLake’s U.S. commercial operations, including sales and marketing, as the company prepares for a potential launch of its lead drug candidate, sonelokimab, the Business Journal reported. The company is a Swiss-founded, clinical-stage biotechnology business whose shares trade on Nasdaq under the symbol MLTX, according to its SEC filings.
The announcement brings a biotech headquarters commitment to an island district more commonly associated with residential and hotel uses. The reported plan is for up to 75 jobs, not confirmation that all positions have been filled or that the office is already operating.
A headquarters tied to launch preparation
MoonLake’s hiring plan is connected to building the commercial infrastructure needed for a possible U.S. introduction of sonelokimab. The company’s annual report describes the drug as an investigational Nanobody being developed for hidradenitis suppurativa and other inflammatory conditions. It is not an approved treatment, according to the company’s 2025 Form 10-K.
A separate company filing provides an update on the regulatory process. In its Form 8-K filed Nov. 4, MoonLake said it submitted a Biologics License Application to the U.S. Food and Drug Administration on Sept. 30, seeking approval of sonelokimab for moderate-to-severe hidradenitis suppurativa. An application is a step in the review process, not an approval.
The distinction matters: the company’s Nov. 4 filing covers its business update and drug program; the Brickell Key headquarters announcement was reported by the Business Journal on Nov. 6. The office plan signals that MoonLake is preparing commercial capacity, but it does not establish when a launch would occur or what the FDA will decide.
The Business Journal reported that the space is in Brickell Key Centre II. The property’s website lists the second office tower at 226,300 square feet. MoonLake’s reported 13,500-square-foot lease would occupy only part of that building.
Illustrative South Florida waterfront scene.
What the 75-job figure does, and doesn’t, tell us
The announced figure is a ceiling: MoonLake plans to hire up to 75 employees at the Miami headquarters, according to the Business Journal. The report identifies sales and marketing among the functions the company expects to build out. The available announcement does not specify the hiring timetable, job titles, salaries or how many positions will be filled locally.
For the region, those details will determine how the plan translates into local employment. A headquarters can involve a range of functions, but the reported figure alone does not establish the eventual mix of roles or the scale of the company’s operations in Miami. The immediate, confirmed commitment is the office lease and a stated plan to hire up to 75 people.
Two corporate moves in the same week
MoonLake’s announcement arrived alongside another headquarters relocation in Miami-Dade. Sucden, a French sugar-trading group, is moving its Latin American headquarters to 255 Alhambra Circle in Coral Gables and relocating about 50 employees, the South Florida Business Journal reported Nov. 6.
The two reported moves are different in sector and scale, but together they put two corporate relocations into the same week’s local business news. MoonLake’s plan is for a biotech U.S. headquarters on Brickell Key; Sucden’s is for a Latin American headquarters in Coral Gables.
Illustrative office-district image; not a depiction of MoonLake’s headquarters.
A measured addition to Miami’s life-sciences story
Life sciences has represented a relatively small share of Miami’s economy. MoonLake’s commitment adds a concrete headquarters lease and a planned team to the region’s case for building a larger biotech presence. But one company’s move is not, by itself, evidence of a fully developed cluster.
The location may also draw attention because it places a biotech headquarters on Brickell Key, an island that has mostly been known for residential and hotel uses. The Business Journal’s report identifies Brickell Key Centre II as the leased site; the property describes itself as an office complex on the island. Beyond those details, the significance is straightforward: a company preparing for a potential U.S. drug launch has selected Miami for its U.S. base and plans to build commercial capacity there.
Illustrative Coral Gables office-district scene; not a depiction of Sucden’s new headquarters.
For now, the key measures to watch are whether MoonLake proceeds with the hiring plan, how the Miami team takes shape and how the FDA reviews sonelokimab. The headquarters selection and up-to-75-person hiring plan are reported commitments; regulatory approval and a commercial launch remain prospective, as reflected in the company’s SEC filings and its Nov. 4 Form 8-K.
